Fri, Jul 11, 2014, 12:28 PM EDT - U.S. Markets close in 3 hrs 32 mins


% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • guinnipigsxxx guinnipigsxxx Nov 7, 2002 2:09 PM Flag

    & where you aware of LEGAL PROCEEDINGS

    Chiron Corporation filed suit on July 30, 1998 against Vertex and Eli Lilly and Company in the United States District Court for the Northern District of California, alleging infringement by the defendants of three U.S. patents issued to Chiron. The infringement action relates to research activities by the
    defendants in the hepatitis C viral protease field and the alleged use of inventions claimed by Chiron in connection with that research. Chiron has requested damages in an unspecified amount, as well as an order permanently enjoining the defendants from unlicensed use of the claimed Chiron inventions. During 1999, Chiron requested and was granted a reexamination by the U.S. Patent
    and Trademark Office of all three of the patents involved in the suit. Chiron also requested and, over the opposition of Vertex and Eli Lilly, was granted a stay in the infringement lawsuit, pending the outcome of the patent re-examination. That reexamination proceeding is still on-going and the stay is
    still in effect. However, a Reexamination Certificate has been issued in two of the three Chiron patents in suit.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Just like all of your other biased, slanted and bashing posts you left the last sentence in the 10K report which reads:
      " ....we maintain that the plaintiff's claims are without merit and intend to defend the lawsuit, if and when it resumes, vigorously." Your publication of these trivial tidbitts shows how desperate you are sir. I would cover my short if I were you. Good day.

98.70+0.88(+0.90%)12:26 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.